The cohort of the multiple sclerosis center of Cagliari.
We report our experience in long-term treatment of relapsing remitting multiple sclerosis patients with natalizumab (N). In November 2009 we evaluated 141 patients (126 AIFA criterion A, 15 AIFA criterion B). We paid particular attention to the treatment period and the patients follow-up; during the whole therapeutic program, they undergone to clinical and radiological evaluation for every 3 months. The compliance was optimal and we found no significant side effects. 26 patients completed the 24 monthly doses. After 24 months 51% of patients were free from disease activity. We found a reduction in relapses and EDSS, moreover the clinical improvement was also confirmed by radiological examinations. Our results show that the best therapeutic results are achieved by early initiation of treatment.
Centro Sclerosi Multipla, Dipartimento di Scienze Cardiovascolari e Neurologiche, Università di Cagliari, Cagliari, Italy. gmarrosu@unica.it
M G
MG
Marrosu
L
L
Lorefice
J
J
Frau
G
G
Coghe
G
G
Fenu
R
R
Piras
M
M
Melis
E
E
Cocco
D000328:Adult; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D015331:Cohort Studies; D019468:Disease Management; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007558:Italy / Q000453:epidemiology; D008279:Magnetic Resonance Imaging / Q000639:trends; D008297:Male; D009103:Multiple Sclerosis / Q000453:epidemiology / Q000276:immunology / Q000628:therapy*; D000069442:Natalizumab; D016019:Survival Analysis; D013997:Time Factors
D061067:Antibodies, Monoclonal, Humanized; D000069442:Natalizumab
Neurol Sci. 2009 Oct;30 Suppl 2:S163-5
19882367
N Engl J Med. 2006 Mar 2;354(9):911-23
16510745
Arch Neurol. 2010 Aug;67(8):923-30
20697042
N Engl J Med. 2003 Jan 2;348(1):15-23
12510038
Ann Neurol. 2001 Jul;50(1):121-7
11456302
Neurology. 2010 Apr 27;74 Suppl 3:S3-7
20421571
N Engl J Med. 2006 Mar 2;354(9):899-910
16510744
Neurology. 2007 May 1;68(18):1524-8
17470756